Estabrook Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Estabrook Capital Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-300	Closed	-$207	–	340
2020 Q4	$207	Hold	300	–	–	﹤0.01%	328
2020 Q3	$675	Hold	300	–	–	﹤0.01%	308
2020 Q2	$1.07K	Hold	300	–	–	﹤0.01%	313
2020 Q1	$1.14K	Hold	300	–	–	﹤0.01%	310
2019 Q4	$903	Buy	+300	New	+$780	﹤0.01%	325

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Estabrook Capital Management's BMY.RT Position: Q1 2021 in Review

Estabrook Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 300 shares — an estimated $207 sold.

Estabrook Capital Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $1.14K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Estabrook Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Estabrook Capital Management sold 300 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $207.
Estabrook Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Estabrook Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1.14K in Q1 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Estabrook Capital Management's 13F filing for Q1 2021, filed 14 May 2021.